Table 2:
Matched comparison between patients with and without neoadjuvant treatment undergoing lobectomy
| Variables | Without neoadjuvant (3824 patients) | With neoadjuvant (3824 patients) | Standardized difference (%) |
|---|---|---|---|
| Age (years), mean (SD) | 61.5 (9.2) | 61.6 (8.9) | −1 |
| Female gender, n (%) | 1210 (32) | 1175 (31) | 2 |
| BMI (kg/m2), mean (SD) | 25.1 (4.1) | 25.1 (4.0) | 6 |
| ppoFEV1%, mean (SD) | 71.1 (16.4) | 71.2 (16.2) | −1 |
| CAD, n (%) | 269 (7.0) | 299 (7.8) | 3 |
| CVD, n (%) | 87 (2.3) | 95 (2.5) | −1 |
| Diabetes, n (%) | 109 (2.9) | 119 (3.1) | −2 |
| PS >1, n (%) | 312 (8.2) | 311 (8.2) | 1 |
| Minimally invasive access, n (%) | 795 (21) | 294 (7.7) | 37 |
| pT stage >1, n (%) | 2504 (65) | 2513 (66) | 0.5 |
| pN positive, n (%) | 1765 (46) | 1786 (47) | 1 |
BMI: body mass index; CAD: coronary artery disease; CVD: cerebrovascular disease; pN: pathological nodal stage; ppoFEV1: predicted postoperative forced expiratory volume in 1 s; PS: performance score; pT: pathological tumour stage.